observed that the course of AIA in Il9 −/− mice was highly chronic (Fig. 1a) . While joint swelling resolved spontaneously within 12-16 d in wild-type mice, it persisted beyond 42 d without signs of resolution in Il9 −/− mice. The chronic inflammatory phenotype of Il9 −/− mice was rescued by overexpression of IL-9 via hydrodynamic gene transfer (HDGT), using minicircle (MC) vectors encoding IL-9 (Il9 MC) (Fig. 1b) . Histological analysis of the affected knee joints of Il9 −/− mice at day 42 confirmed persistent synovitis and demonstrated excessive degradation of cartilage and bone and higher numbers of osteoclasts as compared to wild-type mice ( Fig. 1c-e) . Microcomputed tomography showed pronounced loss of the trabecular network and bone volume as signs of inflammation-induced osteopenia in Il9 −/− mice (Fig. 1f) . In contrast to AIA, absence of IL-9 did not affect the course of acute inflammatory arthritis induced by monosodium urate crystals, which exclusively relies on neutrophil activation (Supplementary Fig. 1b) .
Mice expressing the transgenic T cell receptor (TCR) KRN and the major histocompatibility complex (MHC) class II allele A g7 (K/BxN mice) develop autoantibodies against glucose-6-phosphate isomerase 11 . Passive transfer of serum from these mice is commonly used to initiate chronic arthritis (serum-transfer-induced arthritis, SIA) 12 , with inflammation persisting over several weeks. To assess the therapeutic potential of IL-9 to promote its resolution, we overexpressed IL-9 using HDGT during the effector phase of SIA (3 d after induction of SIA). Consistent with our previous findings in AIA, overexpression of IL-9 did not have major effects on the initiation phase of SIA or on the maximal intensity of arthritis, but it strongly accelerated resolution (Fig. 2a) . Joint swelling completely resolved within 9 d in mice with forced expression of IL-9, whereas arthritis in mice injected with the control vector was still worsening at day 9 ( Fig. 2a,b) . Histological analysis at day 9 showed substantially less synovitis in the paws of mice injected with Il9 MC (Fig. 2b,c) . Accelerated resolution of arthritis by IL-9 translated into reduced tissue damage with preservation of cartilage integrity, reduced osteoclast counts and decreased bone erosions ( Fig. 2b-e) .
To further characterize the mechanism by which IL-9 fosters the resolution of arthritis, the kinetics of pro-and anti-inflammatory mediators was analyzed in the serum and joints of arthritic Il9 −/− and wild-type mice ( Fig. 3a and Supplementary Fig. 2a,b) . Time kinetics and concentrations of most key cytokine mediators such as tumor necrosis factor (TNF)-α, IL-6, interferon (IFN)-γ, IL-2 and IL-4 did not significantly differ between wild-type and Il9 −/− mice. However, pronounced differences in IL-17 levels were observed, and these levels remained persistently high in Il9 −/− AIA mice but returned to baseline levels in wild-type AIA mice. The selective upregulation of IL-17 was associated with enhanced T helper type 17 (T H 17) polarization, particularly in inflamed joints of Il9 −/− mice, whereas naive, memory and effector T cell counts were comparable in wild-type and Il9 −/− mice (Fig. 3b,c ). These data demonstrate a shift to a persistent T H 17 cell-driven immune response in Il9 −/− mice. To address the possibility that IL-9 serves as an intrinsic regulator of T H 17 differentiation, CD4 + T cells from wild-type and Il9 −/− mice were stimulated under T H 17-inducing conditions. Differentiation into conventional as well as inflammatory T H 17 cells was comparable in wild-type and Il9 −/− mice ( Fig. 3d) , providing no evidence for an intrinsic defect in T H 17 development in Il9 −/− mice but arguing for a central role of other cell types in the IL-9-induced inhibition of T H 17 polarization.
To identify these target cells of IL-9, we next analyzed regulatory T reg cells in wild-type and Il9 −/− mice at day 42 after immunization, when inflammation was resolved in wild-type mice but still persisted in Il9 −/− mice. Total numbers of CD4 + CD25 + Foxp3 + T reg cells were comparable in Il9 −/− and wild-type mice (Fig. 3e) . However, the suppressive capacity of T reg cells from Il9 −/− mice was significantly decreased, as shown by coculture of CFSE-labeled CD25 − Foxp3 − effector T (T eff ) cells with Foxp3 + T reg cells and subsequent analyses of proliferation of T eff cells (Fig. 3f) . The functional defect of Il9 −/− T reg cells was associated with significantly decreased Microcomputed tomography scans and assessment of microarchitectural parameters of tibial bone in control and AIA wild-type and Il9 −/− mice (n = 6 for each group) at 14-16 weeks of age. BV/TV, bone volume per total volume; Tb.Th, trabecular thickness. Data are shown as mean ± s.e.m. Scale bars, 100 µm. *P < 0.05, **P < 0.01, ***P < 0.001, Student's t test (a, c-f) or one-way ANOVA with Tukey's post hoc test (b) for experiments including more than two groups in one experiment.
expression levels of functionally important effector molecules 13, 14 such as GITR and ICOS in Il9 −/− T reg cells (Fig. 3g) . To exclude the possibility that T eff cells from Il9 −/− mice are resistant to the effects of T reg cells, the susceptibility of Il9 −/− and wild-type T eff cells to the suppressive effects of wild-type T reg cells was assessed. Neither proliferation nor cytokine production differed between Il9 −/− and wild-type responder T cells (Fig. 3h,i) .
In line with previous reports, exogenous IL-9 modestly enhanced T reg function in vitro (data not shown) 15 . However, prestimulation of T reg cells from Il9 −/− mice with IL-9 and adoptive transfer of these cells into Il9 −/− mice did not prevent chronification of AIA ( Supplementary  Fig. 3a) . We therefore further aimed to define cellular intermediates that might be involved in IL-9-induced resolution of inflammation. To explore the source of IL-9 in arthritis, AIA was induced in Il9 citrine reporter mice 16 . The majority of IL-9-producing cells did not express the lineage (Lin)-specific markers that define Lin + lymphocytic and myeloid populations, including potential IL-9-producing cell types such as T helper type 9 (T H 9) cells [17] [18] [19] [20] and mast cells 21 ( Fig. 4a) . More than 80% of the Lin − citrine + cells expressed ST2, ICOS (Fig. 4a) , CD25, CD90 and Sca-1 (Supplementary Fig. 3b ), suggesting that ILC2s are the predominant source of IL-9 during the resolution phase of arthritis, as defined as the segment of time between the peak of inflammation and 50% regression 22 (Fig. 4a) .
These data were supported by quantitative analysis of synovial tissue sections from wild-type AIA mice stained with immunofluorescencelabeled antibodies. ILC2s were identified as the major source of IL-9 during resolution of AIA (Supplementary Fig. 3c ). Furthermore, expression levels of mast cell-specific genes in inflamed joints did not differ between wild-type and Il9 −/− mice ( Supplementary Fig. 3d,e) . ILC2 numbers were profoundly decreased in the synovium of Il9 −/− mice (Fig. 4b) . Impaired proliferation may account for the reduced numbers of ILC2s, as the number of proliferating Ki67 + ILC2s was significantly decreased in the arthritic knee joints of Il9 −/− mice (Fig. 4b) . In line with previous reports that IL-9 production by ILC2s acts in an autocrine loop to promote ILC proliferation 23, 24 , induction of ILC2s by overexpression of IL-25 and IL-33 using HDGT confirmed an intrinsic defect of ILC2 proliferation in Il9 −/− mice ( Supplementary  Fig. 4a ). Addition of IL-9 led to complete reconstitution of ILC2s. Confirming the relevance of this finding for the pathogenesis of chronic arthritis, multicolor immunofluorescence microscopy (IF) revealed that IL-9-producing ILC2s were located in close proximity to CD3 + Foxp3 + T reg cells in the inflamed synovium (Fig. 4c) . The colocalization of ILC2s and T reg cells in the inflamed tissue supports the notion of cellular interactions that might be of functional relevance for T reg suppression. Indeed, stimulation of ILC2s with IL-9 induced upregulation of the T reg -receptor-associated ligands GITRL and ICOSL (Fig. 4d) .
To determine the functional impact of interactions between ILC2s and T reg cells, we performed T reg suppression assays in the presence and absence of ILC2s. These assays demonstrated that ILC2s stimulated the suppressive capacity of T reg cells. Whereas Il9 −/− T reg cells alone did not suppress T eff proliferation, addition of ILC2s completely rescued this impaired suppressive capacity of Il9 −/− T reg cells (Fig. 4e) . Transwell experiments revealed that these ILC2-mediated effects on Il9 −/− T reg cells required direct cell contacts (Supplementary Fig. 4b ). Screening for potential mediators of this contact-dependent effect showed that ILC2s express high levels of GITRL and ICOSL, which are known to promote the suppressive capacity of T reg cells 13, 14 . Blockade of GITR-GITRL and ICOS-ICOSL interaction reversed the ILC2-mediated effects on the suppressive capacity of Il9 −/− T reg cells (Fig. 4e) . Consistent with this model, ligand binding to GITR and ICOS on Il9 −/− T reg cells also restored the suppressive capacity of Il9 −/− T reg cells in the absence of ICOSL/GITRL-bearing ILC2s (Fig. 4f) . In vivo, adoptive transfer of Il9 −/− T reg cells that had been preactivated via GITR and ICOS ex vivo led to these cells regaining their suppressive activity in the AIA model (Fig. 4g) , highlighting that receptor-ligand specific interactions between ILC2s and T reg cells activate the suppressive capacity of T reg cells. To confirm the functional impact of ILC2s on the resolution of inflammation, ILC2s were adoptively transferred into Il9 −/− mice with AIA. Adoptive transfer of ILC2s inhibited activation of T H 17 cells and promoted resolution of inflammation in Il9 −/− mice ( Fig. 4h and Supplementary Fig. 4c) .
To investigate the role of IL-9 for the resolution of inflammation in humans, synovial tissues of patients with RA were analyzed as prototypical chronic inflammatory joint disease. In line with previous reports 25, 26 , the dominant part of IL-9 expression in the synovial membranes of patients with active RA came from Lin + cells (Fig. 5a,b) . Only low numbers of IL-9 + ILC2s were found in active RA, despite extensive synovial inflammation. In contrast, patients with RA in clinical remission exhibited high numbers of Lin − IL-9 + ILC2s and a significant decline of Lin + IL-9 + cells (Fig. 5a,b) . Patients with acute joint inflammation after trauma demonstrated only a tendency toward increased numbers of Lin + IL-9 + and Lin − IL-9 + cells as compared to healthy individuals. Longitudinal analysis of infiltrates in synovial tissue of patients with RA before and 6 months after the start of anti-inflammatory treatment showed a shift in the cellular source of IL-9 from Lin + IL-9 + cells during active disease to Lin − IL-9 + ILC2s 6 months later when antirheumatic drugs had led to remission of arthritis (Fig. 5c) . Stratification of patients with RA according to disease activity revealed that ILC2 numbers in the blood were particularly low in patients with persistent inflammatory activity, but significantly higher in patients who were in disease remission ( Fig.  5d,e) . ILC2 numbers significantly correlated with disease activity in RA, as measured by standardized disease activity score 28 (DAS28) (Fig. 5e) . Longitudinal observations of patients showed a reciprocal link between ILC2s and disease activity (Fig. 5f ). These data, taken in combination with the results from the mouse models, indicate a pivotal role of ILC2s in the resolution of chronic inflammation and prevention of immunochronicity.
DISCUSSION
Our data demonstrate that IL-9 fosters resolution of inflammation and restores immune homeostasis in arthritis. IL-9 virtually exclusively affected the resolution phase of the disease, while only minor effects were observed in the induction phase. In some experiments, a tendency to higher peak inflammation was observed in IL-9-deficient mice, although these effects were only mild and were not consistent among the experiments. These observations may be explained by the regulatory action of IL-9 starting before the peak of inflammation has been reached. Nonetheless, induction of resolution clearly emerged as the primary action of IL-9 in arthritis, in contrast to the effects of other known cytokines involved in arthritis such as TNF-α, IL-6 and IL-17, which are primarily involved in the induction phase and which are successfully targeted by modern cytokine inhibitors. Our data show that resolution of arthritis is mechanistically based on the induction of ILC2s by IL-9, which in turn elicits GITR-GITRL-and 
Time ( ICOS-ICOSL-dependent activation of T reg cells. This IL-9-mediated forced resolution of arthritis translates into reduced tissue damage such as bone and cartilage loss, which usually result from chronic inflammation in the context of arthritis. Our data provide evidence that IL-9 has a dichotomous function in different phases of inflammation. Previous studies have shown that under certain circumstances IL-9 can promote inflammation in acute models 15, 16, 27, 28 . In chronic arthritis, however, IL-9 acts as a cytokine governing the resolution phase of the disease. These findings are remarkable, as resolution of inflammation has thus far been preferentially attributed to lipid mediators such as resolvins and little was known about innate/adaptive immune system interactions in orchestrating the resolution process 2 . IL-9 and the function of ILC2s in this process provide strong support for the existence of immune pathways that primarily foster the resolution of inflammation and restore immune homeostasis in chronic inflammatory diseases. From a therapeutic perspective, such approaches are highly attractive, as they provide an anchor to allow rebalancing of the pathological inflammatory response in the near future rather than exposing patients to broad suppression of inflammatory responses.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Experimental approaches. Experiments were not performed in a blinded fashion except when specifically indicated. There were no exclusion criteria for the human and animal experiments. Mice were stratified according to sex and then randomized into the different groups. Cells from human donors were also randomized.
Mice. Wild-type BALB/cJRj female mice were purchased from Janvier. BALB/c Il9 −/− mice 29 and Il9 citrine reporter mice 16 were bred in house. Foxp3 GFP reporter mice (C.Cg-Foxp3 tm2Tch /J) were purchased from Jackson Labs and backcrossed on BALB/c Il9 −/− mice to generate Il9 −/− × Foxp3 GFP reporter mice. CD45.1 mice were kindly provided by D. Mielenz (Nikolaus Fiebiger Center). All mice were bred under specific-pathogen-free conditions, and all studies were approved by the animal ethical committee of the government of Unterfranken, Würzburg, Germany.
Patient characteristics. For synovial tissue analyses (ILC2, IL-9-expressing cells), samples from untreated patients with active RA (n = 19) and patients with RA in remission receiving treatment with disease-modifying antirheumatic drugs (methotrexate, n = 15; TNF inhibitors, n = 5) were analyzed (n = 19). Samples were retrieved by synovial biopsy in centers from Barcelona, Dublin and Erlangen, Germany. Subjects with RA fulfilled the 2010 American College of Rheumatology (ACR) classification criteria for RA 30 . Remission was defined by a DAS28 of less than 2.6 (ref. 31 ). There was no significant difference in sex distribution (65.0% versus 73.7%), age distribution (52.3 ± 19.8 years versus 52.9 ± 18.2 years), rheumatoid factor status (67.4% versus 63.1%) and status of antibodies to citrullinated protein (58.5% versus 68.4%) between the two groups. Disease activity in the active RA group was 5.8 ± 1.4 according to DAS28, while it was 1.9 ± 0.5 in the remission group.
In addition, a longitudinal biopsy cohort of ten patients with early RA (disease duration of <12 months) from London undergoing synovial biopsies at baseline and 6 months after the start of antirheumatic therapy was analyzed. 70% were females, the mean age was 49.8 ± 22.6 years, and 70% had rheumatoid factor or antibodies to citrullinated protein. Disease activity at baseline was 5.1 ± 1.2 and at follow-up was 2.0 ± 0.6. Patients received treatment with either methotrexate monotherapy or a combination of methotrexate and/or sulfasalazine and/or hydroxychloroquine. For control purposes, synovial tissue from patients with acute trauma (n = 8) resembling acute inflammation after joint injury were investigated. In addition, normal synovium was used as control tissue, which was obtained from surgery specimens of patients with no articular disease process (n = 11). Written informed consent was obtained from all subjects. The study was approved by the ethical committee of the University of Erlangen-Nürnberg.
For the analysis of circulating ILC2s, a cohort of 111 patients with RA was analyzed. 73.9% were females, the mean age was 59.9 ± 14.3 years and the mean disease activity was 3.2 ± 1.3 according to DAS28. With respect to autoantibody status, 69.4% were positive for rheumatoid factor and 59.5% were positive for antibodies to citrullinated protein. With respect to antirheumatic treatment, 56.8% were treated with methotrexate and 28.8% were treated with biological antirheumatic drugs, mostly TNF inhibitors. 63 of these 111 patients received a follow-up assessment of circulating ILC2s 6 to 12 months after baseline assessment.
Assessment of circulating ILC2s in human blood. Venous human blood was collected with a standard collection system and EDTA as anticoagulant (Sarstedt). The collected blood was processed for routine automated complete blood count. Furthermore, 500 µl of whole blood was directly incubated with the fluorochrome-labeled antibodies listed in Supplementary Table 1 . Following incubation with antibodies, red blood cells were lysed and nucleated cells were fixed using RBC Lysis and Fixation Solution (BioLegend). Flow cytometry was performed on a 3-laser/10-channel flow cytometer system (Navios, CE-licensed, Beckman Coulter) and analyzed using Beckman's proprietary software Kaluza, version 1.5. The gating strategy is shown in Supplementary  Figure 4d . Frequencies of ILC2s (SSC low CD45 + Lin − IL7Ra + cKIT − CRTH2 + ) were calculated as the percentage of lymphocytes (SSC low CD45 high ). Absolute numbers of cells were calculated as follows: % ILC2s × absolute lymphocyte count (automated count) = absolute number of ILC2s per mm 3 .
Antigen-induced arthritis and clinical evaluation. Mouse AIA was induced in female littermates of the stated background that were aged 8 to 10 weeks. Mice were immunized with a booster injection 7 d after by subcutaneous injections with 100 µg of methylated BSA (mBSA) in 100 µl of an emulsion with equal amounts of PBS and complete Freund's adjuvant (all from Sigma-Aldrich). As additional adjuvant, 5 × 10 8 heat-inactivated whole Bordetella pertussis (NIBSC) were administrated intraperitoneally in 100 µl of PBS. 21 d after the initial immunization, mouse AIA was induced in the right knee joint by intra-articular inoculation of 100 µg of mBSA in 25 µl of PBS. The same volume of PBS without mBSA was injected into mice serving as controls. In cases of adoptive transfer of ILC2s, 5 × 10 3 sorted ILC2s were administrated by intra-articular injection together with 100 µg of mBSA in 25 µl of PBS. In a subset of experiments, ILC2s were sorted from CD45.1 mice to verify survival and that ILC2s remained within the knee joint (Supplementary Fig. 4e) . For adoptive transfer of T reg cells, T reg cells were sorted as CD4 + CD25 high cells using non-depleting clones. For some experiments, T reg cells were concentrated to 1 × 10 6 cells/ml and pre-incubated with recombinant mouse IL-9 (50 ng/ml; Immunotools) or a combination of recombinant mouse ICOSL (1 µg/ml; Abcam) and agonistic antibody to GITR (10 µg/ml; clone DTA-1, BioLegend) in complete IMEM overnight. 0.5 × 10 6 T reg cells were adoptively transferred by intravenous injection in 100 µl of Ringer's solution. Animals were inspected every second day for arthritis development, and knee joint diameters were measured using a digital micrometer (Kroeplin). The difference in joint diameter measured before and after inoculation was used as a quantitative measure of swelling (in mm). In a subset of experiments, mice underwent HDGT with Il9 MC DNA 1 d after inoculation (day 22).
Serum-transfer-induced arthritis and clinical evaluation.
Female mice aged 8 weeks on the BALB/cJRj background were induced for SIA by a single intraperitoneal injection of 150 µl of serum generated from the F 1 generation of mice expressing the transgenic TCR KRN crossed onto mice bearing the MHC class II allele Ag7 (K/BxN mice). Serum from these mice is characterized by high serum titers of antibodies against the glycolytic enzyme glucose-6-phosphate isomerase. Animals were inspected every second day for arthritis development, and clinical parameters were monitored, including swelling of the paws and knees and body weight, by a researcher blinded to mouse treatment. Paw and knee swelling is expressed as the difference in paw and joint diameter measured (in mm) before and after injection of serum. Serum was collected for analysis before HDGT, 3 d after HDGT (2 d before serum transfer), and 3 and 9 d after serum transfer.
Injection of monosodium urate crystals as an acute inflammation model. The acute inflammation model has been described elsewhere 32 . Briefly, monosodium urate (MSU) crystals were produced by adjusting a solution of 10 mM uric acid and 154 mM NaCl (both from Merck KGaA) to pH 7.2 and shaking it for 3 d. The resulting crystals were washed in ethanol, dried under sterile conditions, sterilized at 180 °C for 2 h and stored in PBS (pH 7.0). For induction of the acute gout model, 1.5 mg of MSU in 50 µl of PBS was injected subcutaneously into the foot pads of wild-type and Il9 −/− mice. Contralateral foot pads received an injection of 50 µl of PBS serving as a control. Animals were inspected at the indicated time points for paw swelling by a researcher blinded to mouse treatment.
Hydrodynamic gene transfer for induction of ILC2s and IL-9 overexpression.
The principle of HDGT by tail vein injection allowing non-viral introduction of naked foreign plasmid DNA into hepatocytes has been described elsewhere 33, 34 . Briefly, for HDGT, 10 µg of plasmid DNA was applied by tail vein injection into 1 volume of Ringer lactate-free solution corresponding to 10.5% of mouse body weight. For induction of ILC2s, plasmids encoding mouse IL-33 (ref. 35 ) and mouse IL-25 (a kind gift from S. Wirtz) were injected. Mice were sacrificed 60 h after HDGT to isolate ILC2s by flow cytometry-based cell sorting. All plasmids were isolated from their bacterial expression systems using the Invitrogen maxi prep kit (Thermo Fisher Scientific). To ensure efficient endotoxin removal, plasmid DNA was treated with Miraclean endotoxin removal kits (MirusBio). HDGT with Il9 MC DNA was performed on day 22 in the AIA model and 5 d before serum transfer in the SIA model.
Protein concentrations in serum, tissue extracts and cell culture supernatants. Tissue extracts, serum samples and cell culture supernatants were analyzed for secreted cytokines by a flow cytometry-based immune multiplex ELISA (BioLegend) following the instructions in the manufacturer's protocol on a 3-laser/10-channel flow cytometry system (Gallios, Beckman Coulter) and analyzed using Beckman's proprietary software Kaluza version 1.5. IL-9 and IL-33 serum levels were measured by ELISA kits purchased from BioLegend; an IL-25 ELISA kit was purchased from eBioscience. To determine the concentration of cytokines in knees during AIA, mouse knees were homogenized in a non-denaturing protein extraction buffer (100 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM PMSF, 1% protease inhibitor cocktail (Sigma-Aldrich)) using the Precellys Ceramic Kit 2.8 mm on a tissue homogenizer (Peqlab). After homogenization, samples were subsequently centrifuged (18,000g, 20 min, 4 °C) to remove debris. Samples were aliquotted and frozen at −80 °C until analysis by ELISA.
Histological analyses and histomorphometry. Hind legs were fixed overnight in 4% formalin, skin and muscles were rigorously removed and bones were decalcified in 500 mM acid-free EDTA (Sigma-Aldrich) at 4 °C until bones were pliable. Decalcified and paraffin-embedded tibial bones and joints were cut in 5-µm sections and, following deparaffinization and rehydration by standard protocols, stained with H&E, safranin O or TRAP, using a leukocyte acid phosphatase staining kit (Sigma-Aldrich). Safranin O staining was performed according to a standard protocol (IHC world). Loss of safranin O staining was scored as follows: 0, normal; 1, slight reduction; 2, moderate reduction; 3, severe reduction; 4, no dye noted. Synovial inflammation, cartilage destruction and osteoclast numbers were quantified with a Zeiss Axioskop 2 microscope (Carl Zeiss) equipped with the OsteoMeasure system (Osteometrics) as described elsewhere 36 . Representative panorama images were reconstructed using the ImageJ distribution Fiji 37, 38 augmented with the TurboReg 39 and MosaicJ 40 plugins. Scorings and quantifications were performed with blinding to sample identity.
Microcomputed tomography imaging and analysis. Structures of tibial bones and paws were measured with a SCANCO Medical µCT 40 scanner and analyzed with SCANCO evaluation software for segmentation, 3D morphometric analysis, density and distance parameters (SCANCO Medical).
Fluorescence imaging. Epitopes were retrieved from deparaffinized sections using a heat-induced method. Briefly, sections were alternately bathed in boiling sodium citrate buffer (10 mM sodium citrate, pH 6.0) and Tris-EDTA buffer (10 mM Tris base, 1 mM EDTA, 0.05% Tween-20, pH 9.0). Each bathing step was repeated five times for 2 min each. Sections were washed in distilled water and blocked for 1 h in PBS supplemented with 5% BSA and 2% horse serum. Sections were incubated with primary antibodies overnight at 4 °C and with secondary antibodies and DAPI after an intense washing step for 2 h at ambient temperature. Consecutive staining was performed to minimize cross-reactivity. Cross-reactivity was blocked by preincubation with species-specific immunoglobulin. The antibodies used are listed in Supplementary Table 2. Human synovial samples were stained for DAPI, CD3/CD11b/CD16/mast cell tryptase, ICOS and IL-9. Mouse synovial samples were stained for DAPI or Foxp3, ICOS, IL-9 and CD3ε. Sections were finally mounted in fluorescence mounting medium (Dako) and sealed with commercial nail polish. Images were acquired on a Nikon Eclipse 80i fluorescence microscope (Nikon).
Cell isolation for flow cytometry and cell sorting. Mice were sacrificed by cervical dislocation and dissected to generate single-cell suspensions from secondary lymphoid organs (SLOs) and synovial tissue. Fat was thoroughly removed from the dissected SLOs, and their capsules were opened to ensure good drainage of the digestive solution (digestion medium) consisting of RPMI-1640 medium supplemented with 0.4 mg/ml collagenase D from Clostridium histolyticum and 0.2 mg/ml DNase I, grade II, from bovine pancreas (both from Roche Diagnostics). For flow cytometry, single cutaneous lymph nodes were digested in 1 ml of digestion medium at 37 °C for 1 h on a thermoshaker at 1,000 r.p.m. (Eppendorf). Pipetting every 20 min ensured good dissociation of the tissue. Spleens and mesenteric lymph nodes were digested in proportionally higher volumes. The resulting single-cell suspension was filtered through a 70-µm cell strainer and washed in a larger volume of RPMI-1640 medium supplemented with 10 mM EDTA and 10% FCS (stop medium). To generate single-cell suspension from synovial tissue for flow cytometry analysis, whole legs were dissected and muscles and tendons were thoroughly removed. It was especially ensured that popliteal lymph nodes were removed. The femur and tibia were cut proximal to the knee joint, leaving fragments not longer than a few millimeters. The knee joint was then opened and digested twice for 1 h in 2 ml of enriched digestion medium containing 1 mg/ml collagenase D and 0.2 mg/ml DNase I. The resulting single-cell suspensions after 1 and 2 h were filtered through a 70-µm cell strainer and washed in a larger volume of stop medium. For sorting of lymphoid cells from spleen and mesenteric lymph nodes, the dissected SLOs of one mouse were pooled and digested four times in 3 ml of normal digestion medium for 15-20 min for each digestion. Pipetting before each exchange of the digestion medium ensured good dissociation of the cells. The collected single-cell suspensions were filtered through a 70-µm cell strainer and washed in a larger volume of stop medium. In all cases, RBCs were lysed after digestion by applying self-made ACK buffer for 1.5 min. Lysis was stopped by adding 10× PBS to generate 1× solution. Cells were then washed in PBS supplemented with 5 mM EDTA and 2% FCS and filtered through a 40-µm cell strainer.
In vitro polarization of T helper cells. For in vitro generation of T H 1, T H 2, T H 9 and T H 17 cells, single-cell suspensions from spleen were generated as described above. CD4 + T cells were enriched using a negative-selection magnetic enrichment kit (BioLegend). 1 × 10 6 CD4 + -enriched splenocytes were cultured in 48-well plates precoated with antibody to CD3ε (5 µg/ml; 200 µl/well for >1 h at 37 °C; clone 145-2C11) for 72 h at 37 °C in a humidified atmosphere containing 5% CO 2 . The standard culture medium was IMDM medium supplemented with streptomycin (100 µg/ml), penicillin G (100 U/ml), amphotericin B (0.25 µg/ml), l-glutamine (2 mM; all from Gibco, Life Technologies), β-mercaptoethanol (0.5 mM) and 10% FCS. For undirected activation (T H 0), medium only was supplemented with antibody to CD28 (3 µg/ml; clone 37.51). For T H 1 differentiation, medium was supplemented with antibody to CD28 (3 µg/ml), antibody to IL-4 (10 µg/ml; clone 11B11) and IL-12 (20 ng/ml); for T H 2 differentiation medium was supplemented with antibody to CD28 (3 µg/ml), antibody to IFN-γ (10 µg/ml; clone AN-18) and IL-4 (10 ng/ml). For T H 9 differentiation, supplements included antibody to CD28 (3 µg/ml), antibody to IFN-γ (10 µg/ml; clone AN-18), TGF-β (5 ng/ml) and IL-4 (10 ng/ml). For conventional T H 17 differentiation, medium was supplemented with antibody to CD28 (3 µg/ml), antibody to IFN-γ (10 µg/ml), antibody to IL-4 (10 µg/ml), TGF-β (5 ng/ml) and IL-6 (20 ng/ml). For inflammatory T H 17 differentiation, medium was supplemented with antibody to CD28 (3 µg/ml), antibody to IFN-γ (10 µg/ml), antibody to IL-4 (10 µg/ml), TGF-β (5 ng/ml), IL-6 (100 ng/ml), IL-23 (30 ng/ml), IL-1β (20 ng/ml) and IL-21 (20 ng/ml). All cytokines and antibodies were purchased from BioLegend. For flow cytometry analysis, cells were restimulated with 81 nM phorbol 12-myristate 13-acetate (PMA) and 1.3 µM ionomycin in the presence of 5 ng/ml brefeldin A and 2 nM monensin (all from BioLegend) for 5 h.
Staining of single-cell suspensions for flow cytometry. For flow cytometry analysis, 1 × 10 6 cells were stained in a V-shaped 96-well microtiter plate. All antibodies and DAPI were diluted in PBS supplemented with 5 mM EDTA and 2% FCS. 100 µl of staining solution was used per well. Fixable viability dye was diluted in serum-free PBS as stated in the manufacturer's protocol. For cytoplasmic staining of cytokines, before staining, single-cell suspensions were stimulated for 5 h as described above. The intracellular fixation and permeabilization buffer set (eBioscience) was used as recommended in the manufacturer's instructions. For intranuclear staining of Foxp3 and Ki67, the Foxp3 staining buffer set (eBioscience) was used as recommended in the manufacturer's instructions. Concentrations of antibodies and other staining reagents are listed in Supplementary Table 3 . Flow cytometry data were acquired on a 3-laser/10-channel flow cytometer system (Gallios, Beckman Coulter) and analyzed using Beckman's proprietary software Kaluza, version1.5.
Staining of single-cell suspensions for sorting. For sorting of T cell and ILC2 populations from SLOs, single-cell suspensions were concentrated to 40 × 10 6 cells/ml and staining was performed in PBS supplemented with 5 mM EDTA and 2% FCS. Cells were sorted with a jet-in air system (MoFlow Astrios, Beckman Coulter) equipped with a 70-µm nozzle at the Core Unit of Cell Sorting and Immunomonitoring, Friedrich Alexander University (FAU) Erlangen-Nürnberg.
